ContractCredit Agreement • December 10th, 2010 • Cephalon Inc • Pharmaceutical preparations • New York
SIXTH AMENDMENT dated as of December 7, 2010 (this “Amendment”), to the CREDIT AGREEMENT dated as of August 15, 2008, as heretofore amended (as so amended, the “Credit Agreement”), among CEPHALON, INC., a Delaware corporation, the LENDERS party thereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent.
Cephalon and Mesoblast Enter Into Strategic Alliance to Develop and Commercialize Novel Therapeutic Products for Regenerative Medicine Agreement Provides Cephalon with Global Rights in Three Treatment Areas to Products Derived from Mesoblast’s...Cephalon Inc • December 10th, 2010 • Pharmaceutical preparations
Frazer, PA and Melbourne, Australia — December 7, 2010 — Cephalon, Inc. (Nasdaq: CEPH) and Mesoblast Limited (ASX:MSB; USADR:MBLTY), today announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems. These conditions include Congestive Heart Failure, Acute Myocardial Infarction, Parkinson’s Disease, and Alzheimer’s Disease. The alliance also extends to products for augmenting hematopoietic stem cell transplantation in cancer patients.
